ROS1-Rearranged Non-Small-Cell Lung Cancer, Factor V Leiden, and Recurrent Venous Thromboses

Cancer-related venous thromboembolic events are a significant morbidity and mortality burden. The risks of venous thromboembolic events vary with cancer location, stage, preexisting thrombophilia conditions, and possibly with driver mutations. In combination, these risks may be synergistic despite each factor being a minor risk independently. Despite the availability of targeted therapy for ROS1 rearranged non-small-cell lung cancer, there is increasing evidence of a poorer outcome group with rapid decline and progression of disease; the mechanisms are still unknown, and interaction with coagulation system may be a potential factor. Thromboprophylaxis for increased- or multiple-risk patients needs to be individually tailored and closely monitored. (C) 2018 Elsevier Inc. All rights reserved.